Liverpool platform will support nanomedicine developers

A new platform to support companies that are developing cutting-edge treatments for infectious diseases has been established at the University of Liverpool.

A new agreement will see The Nanotherapeutics Hub, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT), work with the Infection Innovation Consortium (iiCON) to support the development of nanomedicines.

Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of delivery for drugs that can reach places drugs normally couldn’t reach otherwise. It is a market projected to be worth more than £150bn by 2026.

Led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), iiCON is revitalising the UK’s infectious diseases product pipeline.